Amgen, Watson Aim For First Joint Oncology Biosimilar In 2017 To Open International Doors
This article was originally published in PharmAsia News
Executive Summary
The deal is a key part of both companies’ plans for aggressive international expansion because they will be able to spread fixed costs and offer robust portfolios to vastly different geographically diverse customers.